Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) (DHELIVER)

Cellaion

Status and phase: Terminated; Phase 2

Conditions: Acute on Chronic Liver Failure

Treatments: Drug: Placebo; Drug: HepaStem

Study type: Interventional

Funder types: Industry

Identifiers

NCT04229901

HEP102

Details and patient eligibility

About

This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 2 infusions of a 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.

Enrollment: 133 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Are adults aged between 18 and 75 years old.
2. Have an initial diagnosis of ACLF at the investigational site.
3. Have ACLF grade 1 or 2 according to the EASL-CLIF Consortium definition.
4. Have a total bilirubin ≥ 5 mg/dL.
5. Are able to read, understand and give written informed consent.

Main Exclusion Criteria:

1. Have a MELD-Na score > 35.

2. Have underlying cirrhosis due to biliary disease.

3. Have underlying cirrhosis due to autoimmune hepatitis.

4. Have active bleeding at a non-compressible site or at a compressible site that, in the opinion of the investigator, poses an unacceptable risk for the patient's participation in the study.

5. Have received treatment for bleeding complications during the current hospitalization and has a persistent high risk for re-bleeding that, in the opinion of the investigator, poses an unacceptable risk for the patient's participation in the study.

6. Have a complete portal vein thrombosis.

7. Have coagulation disturbances defined as:

   • fibrinogen < 80 mg/dL
   • platelets < 50 x 10³/mm³

8. Are requiring chronic dialysis therapy.

9. Have had a cerebrovascular, myocardial, limb arterial thrombotic event, or history for both thrombotic and hemorrhagic cerebrovascular events within 12 months prior to the Screening and not considered stabilized by the investigator.

10. Have a previous history of myocardial infarction and/or cardiac failure, with an ejection fraction rate (EFR) ≤ 40%.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

133 participants in 2 patient groups, including a placebo group

HepaStem

Experimental group

Description:

Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 million of cells/kg of total body weight (7 day interval)

Treatment:

Drug: HepaStem

Placebo

Placebo Comparator group

Description:

Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)

Treatment:

Drug: Placebo